Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Provided By GlobeNewswire
Last update: Aug 6, 2025
Company Discontinuing Development of Cibotercept (KER-012)
Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure
and Strategic Realignment
